Background

Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis carries a devastating complication: rapidly progressive interstitial lung disease (RP-ILD), with mortality rates exceeding 50% when treatment is delayed. Current biomarkers—KL-6, ferritin, and IL-18—rise relatively late in the pathogenic cascade, often leaving clinicians reacting to established disease rather than intercepting early fibroinflammatory injury. The TAM receptor tyrosine kinase family member Axl and its ligand Gas6 constitute a critical regulatory axis governing macrophage efferocytosis (clearance of apoptotic cells) and resolution of inflammation. Defective Gas6/Axl signaling results in persistent apoptotic debris, DAMP release, and amplification of type I interferon responses—a pathogenic loop central to MDA5-positive DM.

Hypothesis

We hypothesize that serial measurement of serum soluble Axl (sAxl) receptor concentration combined with a functional Gas6-dependent efferocytosis capacity index (ECI) in peripheral blood monocytes identifies a pre-fibrotic inflammatory phase in anti-MDA5 dermatomyositis 4–12 weeks before KL-6 elevation or HRCT progression. Specifically:

1. Rising sAxl concentrations (reflecting increased membrane Axl shedding by ADAM10/ADAM17 proteases under interferon stimulation) indicate escalating alveolar epithelial injury and macrophage activation.
2. Declining ECI (measured via ex vivo pHrodo-labeled apoptotic cell uptake assay in autologous monocytes, normalized to Gas6 concentration) reflects functional impairment of the resolution machiner

Hypothesis – Senescent cells establish a biphasic microenvironment through distance‑graded secretion of SASP factors that is shaped by local extracellular matrix (ECM) crosslinking. Within a short‑range radius (≈0‑20 µm) senescent cells deposit lysyl oxidase (LOX)‑mediated collagen and fibronectin crosslinks that trap high‑molecular‑weight growth‑factor‑rich SASP (e.g., FGF2, IGF‑1) near the source, promoting proliferation of neighboring stem/progenitor cells. Beyond this radius, LOX‑crosslinked mesh becomes porous, allowing diffusion of lower‑molecular‑weight inflammatory SASP (IL‑6, CCL2, MMPs) that dominate at intermediate (20‑50 µm) and far (>50 µm) distances, driving microglial activation, secondary senescence, or apoptosis. The switch from regenerative to detrimental signaling is therefore not a fixed property of the senescent cell but a biophysical consequence of age‑dependent ECM remodeling that dictates the spatial reach of distinct SASP moieties.

Mechanistic Rationale – Recent spatial transcriptomics shows inflammatory microdomains radiating from p16^INK4a^+ cells in aged brain [1] and regenerative niches in muscle [2], yet no study has quantified how SASP composition changes with measured distance. The accumulation of senescent cells with age increases both their production and their half‑life [6], which should amplify ECM deposition via the senescence‑associated secretory phenotype’s LOX component—a pathway already implicated in fibrosis and stem‑cell niche modulation [8]. If LOX activity creates a diffusion barrier that preferentially retains bulky gro

Hypothesis

We hypothesize that a longitudinal multi‑omic network signature—combining baseline plasma proteomics, metabolomics, and transcriptomic shifts measured every three months—predicts the onset of frailty within 12 months in adults aged ≥65 with two or more chronic conditions.

Rationale

Multi‑omics platforms have shown promise in oncology and cardiovascular disease by linking molecular layers to clinical outcomes (1, 2). However, most applications remain static and disease‑specific, overlooking the systemic crosstalk that drives multimorbidity in aging (5). Recent work shows that phosphoproteomic rewiring and metabolite flux changes precede clinical frailty, suggesting a mechanistic bridge between molecular dysregulation and physiological decline (3). We propose that integrating these layers into a dynamic Bayesian network captures emergent system‑level risk that static models miss.

Novel Mechanistic Insight

We suggest that chronic low‑grade inflammation drives coordinated alterations in kinase‑substrate networks (detectable via phosphoproteomics) and perturbs tryptophan‑kynurenine metabolism (detectable via metabolomics). These coupled changes reduce mitochondrial resilience and muscle protein synthesis, accelerating frailty. By modeling the directionality of these interactions—e.g., inflamm

Hypothesis

Active-phase caloric restriction (CR) enhances autophagic flux specifically in human circulating immune cells through a circadian‑regulated AMPK‑SIRT1‑FOXO3 axis, and this flux predicts improvements in biological aging pace (DunedinPACE) more accurately than systemic metabolic rate or body‑weight changes.

Rationale

CR robustly induces autophagy via mTOR inhibition, AMPK activation, and sirtuin upregulation across tissues [1]. In mice, aligning CR to the active circadian phase extends lifespan up to 35% independent of weight loss [4], suggesting that timing couples nutrient sensing to core clock machinery. Human studies show that 25% CR for two years slowed DunedinPACE by 2‑3%, translating to a 10‑15% mortality risk reduction [2]. Yet metabolic markers such as glucose or temperature poorly predict lifespan under CR, whereas genetic resilience—especially immune and erythrocyte health—does [3]. A newly validated assay enables direct measurement of autophagic flux in human blood cells [5], providing a tractable read‑out of the proposed mechanism.

We propose that the molecular link between timing and autophagy hinges on circadian control of NAD+ synthesis. During the active phase, NAD+ peaks, activating SIRT1, which deacetylates and activates AMPK and FOXO3, driving transcription of autophagy genes (LC3B, ATG5, BNIP3). Misaligned CR blunts this NAD+ surge, attenuating AMPK‑SIRT1‑FOXO3 signaling and thus autophagic flux, even if caloric intake is equally reduced.

Testable Predictions

1. Participants undergoing active‑phase CR (e.g., 20% calorie reduction co

Hypothesis

Age‑related synaptic loss stems not only from dysregulated complement signaling but also from a failure to sustain CD47 "don’t eat me" signals on metabolically active synapses. Boosting neuronal NAD+ restores CD47 expression via SIRT1‑mediated deacetylation, thereby shifting the C1q/CD47 balance toward preservation of high‑activity circuits and maintaining cognitive function despite ongoing neural firing.

Mechanistic Rationale

1. Neuronal activity and NAD+ consumption – Sustained firing increases ATP demand, draining NAD+ pools and reducing SIRT1 activity [1]. Low SIRT1 leads to hyperacetylation of histones at the Cd47 promoter, decreasing its transcription.
2. CD47 loss tips microglial decision‑making – Microglia interpret reduced CD47 as an “eat me” cue, amplifying C1q‑driven phagocytosis of synapses that are still functionally relevant [2].
3. SIRT1 activation restores CD47 – NAD+ precursors activate SIRT1, which deacetylates NF‑κB p65, reducing inflammatory transcription and directly increasing Cd47 gene expression [3]. Elevated CD47 reinstates the inhibitory signal, protecting active synapses from complement‑tagged removal.
4. Preservation of plasticity reserve – Neurons that retain CD47 maintain synaptic integrity, preserving the plasticity reserve observed in low‑activity cells during aging [1]. This creates a selective advantage for circuits that continue to fire, counteracting the hypothesis that all high‑activity neurons are indiscriminately culled.

Predictions and Experimental Design

• Prediction 1: In aged mice, nicotina

Hypothesis

Integrated spatial proteogenomic and metabolomic profiles reveal layer‑specific discordance that precedes clinical resistance to targeted therapy, and measuring this discordance predicts non‑response earlier than bulk multi‑omics signatures.

Mechanistic Rationale

Single‑cell proteomics shows that protein abundance often diverges from transcript levels due to post‑translational modifications, while metabolomics reflects pathway flux. In tumor microenvironments, stromal cues induce rapid phosphorylation of signaling proteins without corresponding mRNA changes, altering metabolic enzyme activity and creating a mismatch between the proteomic and metabolomic layers. Bulk averaging masks these transient shifts, but spatial preservation captures them. Recent multi‑omics studies demonstrate that organ‑specific plasma proteome links to imaging phenotypes invisible in genomics alone (Organ‑specific plasma proteome links), and that integrated biological age predictors outperform single‑layer clocks by capturing system‑level damage (Integrated biological age predictors). Extending this logic, early therapeutic pressure should produce a detectable proteome‑metabolome discordance within malignant niches before genomic alterations or bulk expression shifts appear.

Testable Predictions

1. It's expected that in patients receiving EGFR‑inhibitor therapy for non‑small cell lung cancer, a rising proteome‑metabolome discordance score in circulating tumor‑derived exos

Hypothesis: Morning bright light exposure within 30 min of waking primes skeletal muscle AMPK activity, such that a subsequent bout of moderate-intensity exercise triggers a synergistic increase in HIF‑1α‑dependent PER2 phosphorylation, leading to a greater advance of the central circadian phase than either stimulus alone, particularly in individuals over 65 years old.

Mechanistic

rationale: Light activation of melanopsin-expressing retinal ganglion cells elevates intracellular Ca2+ and stimulates CaMKKβ‑AMPK signaling in peripheral tissues【1】【2】. Exercise raises the AMP:ATP ratio, directly activating AMPK through LKB1. Convergent AMPK activation phosphorylates HIF‑1α at specific residues, stabilizing it and enhancing its transcriptional co‑activator function on the PER2 promoter, while also facilitating CK1δ/ε‑mediated PER2 phosphorylation that accelerates PER2 degradation and phase advancement【8】. In aging, reduced melanopsin sensitivity diminishes baseline light‑induced AMPK activation【7】; exercise can compensate, but only when preceded by light that “primes” the pathway.

Testable predictions: 1. In adults aged ≥ 65 years, a three‑day regimen of 10,000 lux light for 30 min at 07:30 followed by 30 min of brisk walking at 08:30 will produce a larger phase advance of dim‑light melatonin onset (DLMO) than light alone, exercise alone, or a dim‑light control condition. 2. The additive phase shift will be attenuated by pharmacological AMPK inhibition (Compound C) or HIF‑1α knock‑down in peripheral blood mononuclear cells, as evidenced by reduced p‑AMPK, p‑HIF‑1α,

Aging tissues develop a dual stress state: extracellular matrix becomes 3‑4 fold stiffer due to AGE crosslinks [2] and lysosomes receive increasing loads of undegradable glycated peptides [5]. We hypothesize that under these conditions autophagy does not globally increase bulk degradation but instead rewires its selectivity—diverting autophagosomes toward cytosolic proteins (e.g., damaged mitochondria) while actively deprioritizing the clearance of phagocytosed AGE‑modified ECM fragments. This substrate triage preserves short‑term energy homeostasis at the cost of lysosomal clogging by glycated peptides, which in turn impairs lysosomal acidification and blocks TFEB‑driven transcription of MMPs, explaining the paradox of elevated MMP activity without net matrix turnover [3,6].

Key mechanistic steps: (1) integrin‑β1 signaling on stiff AGE‑collagen activates FAK‑Src, which phosphorylates and inhibits the Ragulator‑Rag GTPase complex, attenuating mTORC1 recruitment to lysosomes specifically on the phagocytic arm of autophagy. (2) Concurrently, glycated peptides bind to lysosomal LAMP2A and competitively inhibit chaperone‑mediated autophagy, shifting cargo preference toward ubiquitin‑dependent, p62‑mediated sequestration of cytosolic proteins. (3) Accumulated undegraded AGE peptides raise lysosomal pH, reducing cathepsin activity and preventing TFEB nuclear translocation, thereby suppressing MMP gene expression despite elevated basal MMP transcription from stress pathways.

Testable predictions: (i) Fibroblasts cultured on tunable hydrogels mimicking young (0.5 kPa) versus

Hypothesis

Delivering resveratrol via pH-responsive β‑cyclodextrin nanoparticles that release cargo at lysosomal pH (≈5) will produce a selective, measurable increase in SIRT1‑dependent deacetylation of native protein substrates (p53‑Lys382 and NF‑κB‑p65‑Lys310) specifically in senescent immune cells, leading to a reduction in the senescence‑associated secretory phenotype (SASP). In contrast, free resveratrol or non‑targeted nanoparticle formulations will not achieve this effect because (i) the assay‑artifact‑driven SIRT1 activation observed with fluorogenic substrates is absent in native contexts, and (ii) resveratrol’s antioxidant activity can inhibit SIRT1 under oxidative conditions unless confined to the acidic lysosomal compartment where its redox state favors deacetylation.

Mechanistic Rationale

1. Lysosomal enrichment of senescent immune cells – Senescent macrophages and T‑cells exhibit heightened lysosomal biogenesis and acidic pH as part of the autophagy‑lysosome axis that sustains the SASP [4]. A pH‑triggered nanoparticle therefore concentrates resveratrol precisely where senescent immune cells are most active.
2. Conformational SIRT1 activation in acidic microenvironments – Resveratrol binds SIRT1 and stabilizes an active conformation that enhances deacetylation of substrates bearing negatively charged groups (e.g., phospho‑ or acetyl‑lysine) when the local pH promotes protonation of catalytic residues. This environment mimics the lysosomal lumen, potentially bypassing the need for fluorophore‑induced artifacts seen in vitro [1,2].
3. **Dec

Hypothesis

Age‑related decline in equol‑producing capacity results from CNS‑to‑gut signaling that alters intestinal oxygen tension, creating a hypoxic niche unfavorable for Lactonifactor longoviformis and other equol synthesizers. Restoring normative mucosal pO₂ via targeted vagal nerve stimulation (VNS) will rescue equol production, downstream SCFA and tryptophan metabolites, and improve neurovascular health.

Mechanistic Rationale

• CNS‑to‑gut endocrine control: Hormone therapy, but not probiotic‑isoflavone co‑administration, increases equol‑producers in post‑menopausal women 1. This indicates systemic endocrine cues shape the gut environment for equol synthesis.
• Equol’s bioactivity: Equol exhibits higher estrogen‑receptor affinity and antioxidant potency than daidzein 2, enabling it to modulate neurovascular function and microglial activation.
• Microbial development: Equol‑producing capacity emerges in childhood alongside increased gut diversity 3, suggesting a maturation‑dependent niche that may erode with age.
• Metabolic interdependence: Low serum S‑equol correlates with reduced SCFA‑producing bacteria and altered tryptophan metabolites 4, linking equol loss to broader gut‑brain axis signaling.

We propose that age‑related rise in sympathetic tone and decline in vagal output increase intestinal e

Hypothesis

NAD+ levels directly license the mitochondrial DNA replication machinery; declining NAD+ reduces the activity of SIRT1‑dependent deacetylation of mitochondrial replication factors, leading to increased mtDNA copy number instability and mutagenesis. Thus, mtDNA damage is a downstream consequence of NAD+ depletion, not an independent driver of aging.

Mechanistic reasoning

• SIRT1 deacetylates and activates TFAM and POLGα, promoting faithful mtDNA replication and nucleoid packaging. When NAD+ falls, SIRT1 activity drops, causing hyperacetylation of TFAM and POLGα, which reduces their DNA binding affinity and polymerase fidelity.
• Hypoacetylated TFAM normally coats mtDNA, protecting it from oxidative damage; hyperacetylated TFAM displaces, exposing the genome to ROS generated by the electron transport chain.
• Reduced NAD+ also impairs the mitochondrial unfolded protein response (UPR^mt) via decreased SIRT3 activity, lowering antioxidant defenses and further increasing ROS pressure on mtDNA.
• Consequently, as NAD+ declines with age, mtDNA suffers increased mutation load and copy number variance, which only becomes phenotypically relevant after a threshold of clonal expansion is reached—a process that follows, rather than precedes, the NAD+ deficit.

Testable predictions

1. Rescue of replication fidelity: Acute NAD+ restoration (e.g., NR or NMN treatment) in aged mice will increase SIRT1 activity, decrease TFAM/POLGα acetylation, and reduce newly arising mtDNA mutations measured by duplex sequencing within 4 weeks, without altering existing mutant clon

Evidence shows that aged tissues exhibit exaggerated UPR flux coupled with mitochondrial DNA heteroplasmy, yet no study has directly lowered heteroplasmy to test whether UPR arm balance improves.

We hypothesize that mitochondrial heteroplasmy acts as a tunable rheostat that skews UPR signaling toward chronic PERK/IRE1 activation and suppresses ATF6‑mediated adaptive transcription, driving senescence.

Mechanistic Rationale

• mtDNA mutations disrupt ER‑mitochondria associated membranes (MAMs), altering Ca²⁺ flux and elevating ROS, which directly modulates the oligomerization state of UPR sensors embedded at MAMs [4].
• Heteroplasmy shifts mitochondrial metabolite ratios (ATP/ADP, NAD⁺/NADH, acetyl‑CoA) that serve as allosteric regulators of PERK autophosphorylation and IRE1 RNase activity, biasing the stress response toward pro‑apoptotic branches.
• Specific mtDNA‑encoded tRNA defects impair mitochondrial translation, creating a mito‑nuclear protein stoichiometry imbalance. This imbalance favors ATF4‑dependent transcription of CHOP while sequestering co‑activators such as CBP/p300 away from ATF6 target promoters, thereby suppressing adaptive UPR output.
• Released mtDNA fragments activate cytosolic cGAS‑STING signaling, which can amplify PERK‑eIF2α‑ATF4 signaling through IRF‑dependent transcriptional cross‑talk, further tilting the UPR arm balance.

Together, these mechanisms position heteroplasmy load as a quantitative dial that sets the set‑point of UPR arm activation.

Experimental Design

1. Model: Use 24‑m

Hypothesis

The anti-aging effects of calcium-α-ketoglutarate (Ca-AKG) depend on its delivery to the nucleus of endothelial cells, where it fuels TET2-mediated DNA demethylation of promoters governing vascular homeostasis. This nuclear AKG-TET2 axis is necessary for the observed lifespan extension, and its efficacy differs between males and females because estrogen up-regulates TET2 expression in females.

Mechanistic Rationale

AKG is a obligate cofactor for the ten-eleven translocation (TET) dioxygenases that oxidize 5-methylcytosine to 5-hydroxymethylcytosine, initiating DNA demethylation [4]. While cytosolic AKG can support mitochondrial metabolism and autophagy, epigenetic reprogramming requires nuclear AKG concentrations that exceed those achieved by systemic supplementation alone [6]. Endothelial cells are particularly sensitive to epigenetic drift because they regulate inflammation, angiogenesis, and blood-brain barrier integrity—processes that deteriorate with age [3]. We propose that Ca-AKG enters endothelial nuclei via the soluble lactate transporter SLC5A8, which is upregulated by shear stress and estrogen signaling [5]. Once inside, AKG sustains TET2 activity, leading to demethylation of promoters for eNOS (Nos3) and Klotho, thereby improving vascular function and reducing senescence-associated secretory phenotype (SASP). Estrogen-dependent enhancement of TET2 transcription in females creates a sex-biased baseline, making females more responsive to nuclear AKG supplementation.

Predictions

1. Endothelial-specific TET2 knockout will abolish the lifespan-e

Hypothesis\n\nIt's becoming clear that the functional age of the gut microbiome—measured by a decline in tryptophan‑derived metabolites such as indole‑3‑propionic acid (IPA)—precedes and predicts systemic inflammaging and neurocognitive decline more accurately than host epigenetic clocks.\n\n## Mechanistic Basis\n\n1. Microbial metabolite loss – Age‑related shifts reduce Clostridium spp. that produce IPA, a ligand for the aryl hydrocarbon receptor (AhR) in intestinal epithelial cells.\n2. Barrier weakening – Reduced AhR signaling lowers expression of tight‑junction proteins and mucin, increasing permeability and allowing LPS translocation Age-related dysbiosis drives systemic inflammation and neuroinflammation through increased intestinal permeability.\n3. Senescent cell amplification – LPS‑triggered TLR4 activation accelerates enterocyte senescence, which in turn secretes SASP factors that further suppress beneficial microbes, creating a feed‑forward loop Reciprocal senescence-dysbiosis loop exacerbates barrier dysfunction and inflammation.\n4. Neuroimmune priming – Circulating LPS and SASP cytokines (IL‑1β, TNF‑α) cross the compromised barrier, priming microglia via TLR4 and NF‑κB, lowering the threshold for subsequent activation by amyloid‑β or tau Increased intestinal permeability allows microbial LPS to activate microglia.\n5. Metabolite‑mediated microglial modulation – Simultaneously, increased

Hypothesis

Quercetin phytosome administered during the hepatic CYP3A4 activity nadir (approximately ZT14‑ZT18 in humans, i.e., early subjective night) generates higher peak aglycone exposure, stronger SIRT1‑dependent BMAL1 acetylation, and superior senescent cell clearance compared with dosing at the enzyme peak (ZT2‑ZT6).

Rationale

It's known that quercetin is a substrate and inhibitor of CYP3A4 and UGT enzymes that exhibit robust circadian oscillations in human liver[2][3]. When CYP3A4 activity's low, less quercetin undergoes oxidative metabolism, preserving more parent compound for cellular uptake and subsequent deglycosylation via phytosome‑mediated transport[1]. Concurrently, quercetin directly modulates core clock components—BMAL1, CLOCK, CRY1/2—and upregulates SIRT1 in peripheral tissues[4][5]. SIRT1 activity is NAD⁺‑dependent and itself clock‑controlled, creating a feedback loop where heightened SIRT1 amplifies BMAL1 transcriptional activity and drives expression of senolytic effectors such as FOXO3 and p53‑mediated apoptosis[4][5]. Dosing quercetin when CYP3A4 is trough therefore maximizes intracellular aglycone availability precisely when the SIRT1‑BMAL1 axis is primed for nocturnal reinforcement, leading to amplified p53‑FOXO3 signaling and increased clearance of SASP‑positive cells.

Predictions

1. Plasma quercetin aglycone Cmax and AUC₀‑∞ will be 1.5‑2‑fold higher after nighttime versus morning phytosome dosing in a crossover PK study.
2. Hepatic SIRT1 activity (measured by deacetylation of PGC‑1α) and BMAL1 acetylation status will show a synergistic

Hypothesis

Rapamycin and caloric restriction (CR) generate nearly identical topological shapes in the manifold of age‑associated gene expression, indicating they activate a shared stress‑response program rather than repairing underlying molecular damage.

Mechanistic Basis

mTOR inhibition triggers AMPK activation and HIF‑1α stabilization, reproducing the low‑energy signaling cascade that occurs during nutrient scarcity. This cascade drives a cyclic transcriptional program where stress‑responsive genes oscillate in coordinated waves, creating persistent loops (1‑dimensional holes) and higher‑order voids (2‑dimensional holes) in the expression space. True damage‑reversal interventions—such as senolytic clearance or NAD⁺ boosting—should collapse these loops by resolving DNA‑damage signalling and reducing transcriptional noise, thereby simplifying the manifold’s topology.

Testable Predictions

1. Persistence diagrams of rapamycin‑treated and CR‑treated old mice will show overlapping Betti‑0 (connected components), Betti‑1 (loops), and Betti‑2 (voids) distributions when computed from the 576 BiT age genes.
2. Senolytic‑treated or NAD⁺‑boosted animals will exhibit significantly lower Betti‑1 and Betti‑2 values, reflecting a reduction in cyclic and void‑like structures.
3. The Wasserstein distance between rapamycin and CR diagrams will be smaller than the distance between either and a genuine repair intervention.

Experimental Design

• Use aged (24‑month) C57BL/6 mice divided into four groups: control, rapamycin (14 ppm diet), 40 % CR, and senolytic combo (dasatinib + 

Hypothesis\n\nLysosomal lipid lock sustains mTORC1‑driven autophagy suppression in aging\n\nMechanistic rationale\n- Mitochondrial dysfunction in aged cells raises ROS and reduces NAD+, leading to AMPK inhibition and persistent mTORC1 activation on the lysosomal surface {3} {2}.\n- Concurrently, impaired lysosomal cholesterol efflux causes accumulation of free cholesterol and oxidized phospholipids within the lysosome lumen and membrane {5}.\n- These lipids disrupt the Ragulator‑Rag GTPase complex, preventing its conformational shift that normally releases mTORC1 during amino‑acid scarcity {6}.\n- As a result, mTORC1 remains tethered to the lysosome irrespective of upstream nutrient signals, keeping ULK1 phosphorylated at Ser757 and blocking autophagy initiation.\n- The block is reinforced by declining cargo receptors (p62, OPTN) and RUBCN up‑regulation, which are downstream consequences of sustained mTORC1 activity {4}.\n\nTestable predictions\n1. In fibroblasts or muscle tissue from old mice, lysosomal cholesterol content will correlate positively with mTORC1 lysosomal localization and inversely with autophagic flux (LC3‑II turnover).\n2. Acute treatment with an LXR agonist (e.g., GW3965) will increase lysosomal cholesterol export, reduce Ragulator‑mTORC1 colocalization, and restore autophagy flux without altering NA